Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson's disease
Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson's disease
复制标题
DOI：
10.1212/wnl.49.5.1424
复制
发表时间：
1997-11-01
期刊：
影响因子：
9.9
通讯作者：
Kobal, G
中科院分区：
文献类型：
--
作者：
Barz, S;Hummel, T;Kobal, G
多位作者报道了帕金森病 (PD) 患者嗅觉功能下降的情况。目前的研究使用嗅觉事件相关电位（OERP）作为嗅觉功能的电生理相关性并结合心理物理测试来研究帕金森病患者的嗅觉。特别关注的是抗帕金森病药物的影响。我们调查了接受抗帕金森病药物治疗的帕金森病患者 (n = 13) 和未接受药物治疗的帕金森病患者 (n = 18)。他们与年龄和性别匹配的对照受试者 (n = 38) 进行了比较。为了获得 OERP，选择兴奋剂来专门刺激嗅觉神经（2.1 ppm 香草醛、0.8 ppm H2S）。此外，用 52% v/v CO2 刺激三叉神经后记录化学感觉事件相关电位。此外，还通过“挤瓶”技术测试了受试者识别和辨别气味的能力。该研究取得了以下主要结果：（1）PD患者的气味识别能力受损。它不受抗帕金森病药物治疗的影响。 (2)服用和不服用抗帕金森病药物的帕金森病患者的OERP潜伏期均延长；然而，这种效应在服用抗帕金森病药物的 PT 患者中更为明显。 (3) 鼻内化学感应三叉神经系统似乎既不受帕金森病中神经元变性的影响，也不受抗帕金森病药物治疗的影响。
Decrease of olfactory function in patients with Parkinson's disease (PD) has been reported by several authors. The current study investigated olfaction in PD patients using olfactory event-related potentials (OERPs) as an electrophysiologic correlate of olfactory function in combination with psychophysical testing. A specific focus was the influence of antiparkinsonian drugs. We investigated PD patients treated with antiparkinsonian drugs (n = 13) and PD patients who received no pharmacologic treatment (n = 18). They were compared to age-and sex-matched control subjects (n = 38). To obtain OERPs, stimulants were chosen to stimulate specifically the olfactory nerve (2.1 ppm vanillin, 0.8 ppm H2S). In addition, chemosomatosensory event-related potentials were recorded after trigeminal stimulation with 52% v/v CO2. Moreover, the subjects' ability to identify and to discriminate odorants was tested by means of a ''squeeze bottle'' technique. The study yielded the following major results: (1) Odor identification was impaired in PD patients. It was not influenced by treatment with antiparkinsonian drugs. (2) The OERP latencies were prolonged in both PD patients taking and not taking antiparkinsonian drugs; however, this effect was mare pronounced in PT) patients taking antiparkinsonian drugs. (3) The intranasal chemosensory trigeminal system seemingly was neither affected by the neuronal degeneration seen in PD nor by treatment with antiparkinsonian drugs.